NO20092019L - Behandling av gjennomtrengende utviklingsforstyrrelser - Google Patents

Behandling av gjennomtrengende utviklingsforstyrrelser

Info

Publication number
NO20092019L
NO20092019L NO20092019A NO20092019A NO20092019L NO 20092019 L NO20092019 L NO 20092019L NO 20092019 A NO20092019 A NO 20092019A NO 20092019 A NO20092019 A NO 20092019A NO 20092019 L NO20092019 L NO 20092019L
Authority
NO
Norway
Prior art keywords
disorder
developmental disorders
pervasive developmental
treatment
pdds
Prior art date
Application number
NO20092019A
Other languages
English (en)
Inventor
Magali Haas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092019L publication Critical patent/NO20092019L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse er en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS) som innbefatter administrering til et subjekt som trenger det en teapeutisk effektiv mengde av en eller flere karbamatforbindelser med formel 1 og/eller formel 2 som definert heri og vist nedenfor. Foreliggende oppfinnelse angår en fremgangsmåte for behandling av pervasive utviklingsforstyrrelser (PDD'er) som inkluderer; autistisk forstyrrelse, Aspergers syndrom, barnedisintegrativ forstyrrelse (CDD), Rett's forstyrrelse og PDD-ikke ellers spesifisert (PPD-NOS), som inkluderer monoterapi og alternativ, kombinasjonsterapi med minst en ytterligere psykoaktiv medisinering.
NO20092019A 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser NO20092019L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31
PCT/US2007/081365 WO2008054984A1 (en) 2006-10-31 2007-10-15 Treatment of pervasive developmental disorders

Publications (1)

Publication Number Publication Date
NO20092019L true NO20092019L (no) 2009-06-23

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092019A NO20092019L (no) 2006-10-31 2009-05-25 Behandling av gjennomtrengende utviklingsforstyrrelser

Country Status (17)

Country Link
US (1) US20080103199A1 (no)
EP (1) EP2089011A1 (no)
JP (1) JP2010508354A (no)
KR (1) KR20090080105A (no)
CN (1) CN101568333A (no)
AU (1) AU2007313911A1 (no)
BR (1) BRPI0718323A2 (no)
CA (1) CA2667909A1 (no)
CO (1) CO6180427A2 (no)
EA (1) EA200970435A1 (no)
GT (1) GT200900112A (no)
IL (1) IL198488A0 (no)
MX (1) MX2009004798A (no)
NI (1) NI200900074A (no)
NO (1) NO20092019L (no)
WO (1) WO2008054984A1 (no)
ZA (1) ZA200903772B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
CN103392182B (zh) 2010-08-02 2017-07-04 众有生物有限公司 用于发现遗传疾病中致病突变的系统和方法
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
DK2766483T3 (da) 2011-10-10 2022-04-19 Hospital For Sick Children Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
HK1214505A1 (zh) * 2012-08-06 2016-07-29 S1制药有限公司 治療方案
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
JP6131341B2 (ja) * 2013-03-12 2017-05-17 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物及びこれを含む精神疾患の予防又は治療用組成物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄａｎｄａｃｏｍｐｏｓｉｔｉｏｎｆｏｒｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇａｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒｃｏｍｐｒｉｓｉｎｇｔｈｅｓａｍｅ｝
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
JP7208139B2 (ja) * 2016-12-14 2023-01-18 エスケー バイオファーマスティカルズ カンパニー リミテッド 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
FI3625368T3 (fi) 2018-08-08 2023-01-13 Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032300A3 (cs) * 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
IL157591A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
DE60216457T2 (de) * 2001-02-27 2007-09-20 Ortho-Mcneil Pharmaceutical, Inc. Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE60221670T2 (de) * 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
HRP20100304T1 (hr) * 2004-09-16 2010-09-30 Janssen Pharmaceutica Nv Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze

Also Published As

Publication number Publication date
CA2667909A1 (en) 2008-05-08
KR20090080105A (ko) 2009-07-23
IL198488A0 (en) 2010-02-17
NI200900074A (es) 2010-02-01
MX2009004798A (es) 2009-08-12
JP2010508354A (ja) 2010-03-18
CO6180427A2 (es) 2010-07-19
EP2089011A1 (en) 2009-08-19
BRPI0718323A2 (pt) 2013-11-26
CN101568333A (zh) 2009-10-28
WO2008054984A1 (en) 2008-05-08
EA200970435A1 (ru) 2009-10-30
ZA200903772B (en) 2010-08-25
GT200900112A (es) 2010-05-18
US20080103199A1 (en) 2008-05-01
AU2007313911A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
BR112013031510A2 (pt) [1,3]oxazinas
NO20084931L (no) Farmasoytiske sammensetninger
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200054A1 (ru) Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
DOP2006000170A (es) Nuevos derivados de espirocromanona
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA201290517A1 (ru) Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application